Higher levels of interleukin 6 (IL-6) and interleukin 8 (IL-8) have been found recently to be linked to reduced responses and worse clinical outcomes to ICI therapies across multiple types of cancers (215–217). The gene discussed is CXCL8; the disease is cancer.